We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility
News

Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility

Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility
News

Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced the expansion of its sterile pharmaceutical manufacturing facility in Glasgow, Scotland. The Company has doubled its capacity for the aseptic (sterile) GMP manufacture of pharmaceuticals to be used in clinical trials with the new facility being operational with immediate effect.

Evotec’s formulations business is a niche provider of contract pharmaceutical development services for the development of formulations of pharmaceuticals intended for parenteral administration and the manufacture of formulated drugs for use in Phase I and Phase II clinical trials.

The expansion of the facilities is in response to the demand from its clients for clinical supplies of liquid and lyophilised drug product. Evotec has demonstrated its expertise in drug formulation development and sterile manufacturing, offering its clients services of the highest quality and technical standards.

These additional facilities will allow Evotec to shorten the lead-time to access its manufacturing capabilities. This will therefore accelerate the progression of Evotec’s clients’ drugs into the clinical stage of drug development.

Advertisement